股四头肌厚度联合白蛋白水平对老年腹腔镜结直肠肿瘤手术患者术后谵妄的预测价值

注册号:

Registration number:

ChiCTR2600116552 

最近更新日期:

Date of Last Refreshed on:

2026-01-12 15:41:12 

注册时间:

Date of Registration:

2026-01-12 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

股四头肌厚度联合白蛋白水平对老年腹腔镜结直肠肿瘤手术患者术后谵妄的预测价值

Public title:

Predictive Value of Quadriceps Muscle Thickness Combined with Albumin Level for Postoperative Delirium in Elderly Patients Undergoing Laparoscopic Colorectal Tumor Surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

股四头肌厚度联合白蛋白水平对老年腹腔镜结直肠肿瘤手术患者术后谵妄的预测价值

Scientific title:

Predictive Value of Quadriceps Muscle Thickness Combined with Albumin Level for Postoperative Delirium in Elderly Patients Undergoing Laparoscopic Colorectal Tumor Surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

詹荣蕾 

研究负责人:

王绍林 

Applicant:

Ronglei Zhan 

Study leader:

Shaolin Wang 

申请注册联系人电话:

Applicant telephone:

+86 198 5500 6196

研究负责人电话:

Study leader's
telephone:

+86 553 390 7271

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1704265099@qq.com

研究负责人电子邮件:

Study leader's E-mail:

wuhuwsl@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

安徽省芜湖市镜湖区渡春路6号

研究负责人通讯地址:

安徽省芜湖市镜湖区渡春路6号

Applicant address:

No. 6, Duchun Road, Jinghu District, Wuhu City, Anhui Province

Study leader's address:

No. 6, Duchun Road, Jinghu District, Wuhu City, Anhui Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

芜湖市第二人民医院

Applicant's institution:

The Second People's Hospital of Wuhu

研究负责人所在单位:

芜湖市第二人民医院

Affiliation of the Leader:

The Second People's Hospital of Wuhu

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025-KY-075

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

芜湖市第二人民医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Wuhu Second People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-11-10 00:00:00

伦理委员会联系人:

吴梦莹

Contact Name of the ethic committee:

Mengying Wu

伦理委员会联系地址:

安徽省芜湖市镜湖区渡春路6号

Contact Address of the ethic committee:

No. 6, Duchun Road, Jinghu District, Wuhu City, Anhui Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 180 0963 1305

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

芜湖市第二人民医院

Primary sponsor:

The Second People's Hospital of Wuhu

研究实施负责(组长)单位地址:

安徽省芜湖市镜湖区渡春路6号

Primary sponsor's address:

No. 6, Duchun Road, Jinghu District, Wuhu City, Anhui Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

安徽

市(区县):

芜湖

Country:

China

Province:

Anhui

City:

Wuhu

单位(医院):

芜湖市第二人民医院

具体地址:

安徽省芜湖市镜湖区渡春路6号

Institution
hospital:

The Second People's Hospital of Wuhu

Address:

No. 6, Duchun Road, Jinghu District, Wuhu City, Anhui Province

经费或物资来源:

自筹

Source(s) of funding:

Self-raised

研究疾病:

术后谵妄  

Target disease:

Postoperative Delirium

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

探讨股四头肌厚度联合血浆白蛋白水平预测老年腹腔镜结直肠肿瘤手术患者术后谵妄的价值,为术后谵妄防治策略的制定提供参考  

Objectives of Study:

To investigate the value of quadriceps muscle thickness combined with plasma albumin level in predicting postoperative delirium in elderly patients undergoing laparoscopic colorectal tumor surgery, and to provide a reference for the development of prevention and management strategies for postoperative delirium.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

(1)患者或监护人拒绝参与本研究;(2)不能完成术前评估;(3)下肢截肢、原发运动功能障碍或明确的神经肌肉疾病;(4)大腿皮肤破损、溃烂、局部感染、重度肥胖等不适宜进行超声检查;(5)患有精神分裂症、严重痴呆、无法读写或语言交流患者;(6)MMSE评分低于25分患者;(7)不愿意遵守协议或程序

Exclusion criteria:

(1) Patients or their guardians refused to participate in this study; (2) Inability to complete the preoperative assessment; (3) Lower limb amputation, primary motor dysfunction, or confirmed neuromuscular disease; (4) Conditions unsuitable for ultrasound examination, such as skin breakdown, ulceration, local infection, or severe obesity in the thigh; (5) Patients with schizophrenia, severe dementia, or those unable to read, write, or communicate verbally; (6) Patients with an MMSE score below 25; (7) Unwillingness to comply with the study protocol or procedures.

研究实施时间:

Study execute time:

From 2025-11-10 00:00:00 To 2027-02-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-01-14 00:00:00 To 2027-02-01 00:00:00

干预措施:

Interventions:

组别:

观察组

样本量:

220

Group:

Observation group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

安徽 

市(区县):

芜湖 

Country:

China

Province:

Anhui

City:

Wuhu

单位(医院):

芜湖市第二人民医院 

单位级别:

三甲 

Institution
hospital:

The Second People's Hospital of Wuhu

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后谵妄

指标类型:

主要指标

Outcome:

Postoperative Delirium

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

股四头肌厚度

指标类型:

次要指标

Outcome:

Quadriceps Thickness

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术前生化检查(白蛋白、血红蛋白等)

指标类型:

次要指标

Outcome:

Preoperative biochemical tests (albumin, hemoglobin, etc.)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

MMSE评分

指标类型:

次要指标

Outcome:

MMSE score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术中出血量、尿量

指标类型:

次要指标

Outcome:

intraoperative blood loss, urine output

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术中补液量、输血量

指标类型:

次要指标

Outcome:

intraoperative fluid infusion volume, blood transfusion volume

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

手术时间、麻醉时间

指标类型:

次要指标

Outcome:

operation time, anesthesia time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术中用药量(右美托咪定、舒芬太尼、糖皮质激素)

指标类型:

次要指标

Outcome:

intraoperative medication dosage (Sufentanil, Dexmedetomidine, corticosteroids)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后并发症

指标类型:

次要指标

Outcome:

postoperative complications

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

住院时间

指标类型:

次要指标

Outcome:

hospital stays

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 65 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

建立CRF本、随访人员进行采集和记录;录入Excel,建立电子数据库

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The Case Report Form binders will be created. Follow-up personnel will compile and document the data, which will then be entered into Excel to establish an electronic database.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-01-12 15:41:07